SCHEMBL1092016

SCHEMBL1092016

CCCc1ncccc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
KDM4E B2RXH2 5/20 0.59
HSD17B10 Q99714 2/20 0.50
CYP2C19 P33261 1/20 0.47
HIF1A Q16665 1/20 0.47
CHRM1 P11229 2/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
CHRM3 P20309 1/20 0.42
IDO1 P14902 1/20 0.41
COMT P21964 2/20 0.41
MMP2 P08253 1/20 0.41
TSHR P16473 1/20 0.41
ADRA1A P35348 1/20 0.41
METAP2 P50579 1/20 0.41
METAP1 P53582 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
KDM1A O60341 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Boric Acid SCHEMBL29141601 0.94 ALDH1A1 (0.55) ALDH1A1L3MBTL1KDM4EHSD17B10CYP2C19
SCHEMBL2386030 0.88 L3MBTL1 (0.57) ALDH1A1L3MBTL1KDM4EHSD17B10CYP2C19
Succinic Acid SCHEMBL15772804 0.88 KDM4E (0.53) ALDH1A1L3MBTL1KDM4EHSD17B10CYP2C19
SCHEMBL1081794 0.86 L3MBTL1 (0.55) ALDH1A1L3MBTL1KDM4EHSD17B10CYP2C19
SCHEMBL28202954 0.85 L3MBTL1 (0.53) ALDH1A1L3MBTL1KDM4EHSD17B10HIF1A
SCHEMBL31121578 0.83
SCHEMBL765054 0.83
SCHEMBL31308700 0.81 ALDH1A1 (0.69) ALDH1A1L3MBTL1KDM4EHSD17B10CYP2C19
SCHEMBL17935320 0.80 ALDH1A1 (0.57) ALDH1A1L3MBTL1KDM4EHSD17B10CYP2C19
SCHEMBL27763191 0.79 ALDH1A1 (0.61) ALDH1A1L3MBTL1KDM4EHSD17B10CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2297100-B1 TETRAHYDROCYCLOPENTA[B]INDOLE ANDROGEN RECEPTOR MODULATORS LILLY CO ELI (US) 2012-10-31 EP disclosed
US-8153634-B2 Carbinol derivatives having cyclic linker KOWA COMPANY, LTD. (JP) 2012-04-10 US disclosed
EP-2281817-A1 SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER Kowa Company, Ltd. (JP) 2011-02-09 EP disclosed
US-20100048610-A1 CARBINOL DERIVATIVES HAVING CYCLIC LINKER KOWA COMPANY, LTD. (JP) 2010-02-25 US disclosed
WO-2009140448-A1 TETRAHYDROCYCLOPENTA[B]INDOLE ANDROGEN RECEPTOR MODULATORS ELI LILLY AND COMPANY (US) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048610-A1 CARBINOL DERIVATIVES HAVING CYCLIC LINKER NR1H2, NR1H3, LDLR ALDH1A1 3636/4885L3MBTL1 2622/4885KDM4E 4240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.